NORTH SHORE - LONG ISLAND JEWISH HEALTH SYSTEM LONG ISLAND JEWISH MEDICAL CENTER DEPARTMENT OF LABORATORY MEDICINE REFERENCE RANGES

Transcription

1 S A2 COLUMN 0D % ACETAMINOPHEN 0D > 150 ug/ml > 50 ug/ml 12 hour post ingestion > 100 ug/ml 8 hour post ingestion > 200 ug/ml 4 hour post ingestion ACTIVATED PROTEIN C RESIS 0D RATIO ALBUMIN 0D g/dl ALBUMIN - FLUID 0D CSF: 40-70% of Total Protein g/dl PERITONEAL FL: g/dl PLEURAL FL: g/dl ALT (SGPT) 0D u/l ALKALINE PHOSPHATASE 0D u/l AMIKACIN - RANDOM 0D > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml AMIKACIN - PEAK 0D > 35 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml AMIKACIN - THROUGH 0D > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 8 ug/ml TRADITIONAL DOSING ug/ml < 8 ug/ml TOXIC VALUES > 35 ug/ml > 10 ug/ml 1 Reviewed: 1/04/13

2 S AMMONIA 0D > 150 umol/l AMNISURE 0D NEGATIVE NEGATIVE AmniSure is an immunochromatographic assay for PAMG-1, an amniotic fluid protein. Detection of PAMG-1 in vaginal fluid is evidence of ruptured fetal membranes. Results should be interpreted in conjunction with clinical and other laboratory findings AMYLASE 0D u/l AMYLASE - FLUID 0D u/l ANTICARDIOLIPIN PROFILE ANTICARDIOLIPIN IgG 0D GPL ANTICARDIOLIPIN IgM 0D MPL ANTI NUCLEAR ANTIBODY 0D NEGATIVE NEGATIVE ANTITHROMBIN 3 ACTIVITY 0D % APTT 0D > 120 SEC ASLO 0D <200 <200 IU/mL AST (SGOT) 0D u/l BARBITURATES - SERUM 0D NEGATIVE NEGATIVE BENZODIAZEPINES - SERUM 0D NEGATIVE NEGATIVE BILIRUBIN - DIRECT 0D mg/dl BILIRUBIN - FLUID 0D mg/dl BILIRUBIN - TOTAL 0D > 15 mg/dl 1D > 15 3D > 15 6D > 15 29D BLEEDING TIME 0D MINS 2 Reviewed: 1/04/13

3 S BNP 0D BNP results less than or equal to 100 pg/ml are representative pg/ml of patients without CHF. BNP results greater than 100 pg/ml are considered abnormal and suggestive of patients with CHF. High BNP concentrations measured in the first 72 hours after an acute coronary syndrome are associated with an increased risk of death, myocardial infarction and CHF. BUN 0D mg/dl BUN - POST DIALYSIS 0D mg/dl BUN - PRE DIALYSIS 0D mg/dl BUN - FLUID 0D CSF: mg/dl SALIVA: 0-14 STIMULATED SALIVA (CHILDREN): PLEURAL FLUID: BUN - URINE 24 HOUR 0D mg/24 HR C3 0D mg/dl C4 0D mg/dl C. DIFFICILE TOXIN by PCR 0D NOT DETECTED NOT DETECTED C. DIFFICILE TOXIN CYTOTOXICITY 0D NEGATIVE NEGATIVE C PEPTIDE 0D ng/ml C REACTIVE PROTEIN 0D mg/l CAFFEINE 0D > 80 ug/ml CALCIUM 0D < 6.5 > 13.0 mg/dl CALCIUM - FLUID 0D mg/dl CALCIUM - URINE 24 HOUR 0D mg/24hr The 24 hour excretion of calcium is highly diet dependent. General guidelines are as follows: Calcium free diet: 5-40 mg/day Low to average: mg/day Average (800 mg/day): mg/day 3 Reviewed: 1/04/13

4 S CALCIUM - IONIZED 0D < 0.7 mmol/l CARBAMAZEPINE 0D > 14 ug/ml CEA - CARCINOEMBRYOGENIC ANTIGEN 0D ng/ml CHLAMYDIA DNA PROBE 0D NEGATIVE NEGATIVE CHLORIDE 0D mmol/l CHLORIDE - CSF 0D meq/l CHLORIDE - FLUID 0D meq/l GASTRIC JUICE: BILE: PANCREATIC JUICE: SMALL BOWEL: ILEOSTOMY: CHLORIDE - SWEAT 0D mmol/l INTERPRETATION OF RESULTS: Sweat Chloride for infants < 6 months old: Negative <= 29 mmol/l Borderline / Indeterminate mmol/l Positive >= 60 mmol/l Consistent with a diagnosis of Cystic Fibrosis Sweat Chloride for patients >= 6 months old: Negative <= 39 mmol/l Borderline / Indeterminate mmol/l Positive >= 60 mmol/l Consistent with a diagnosis of Cystic Fibrosis Sweat weight was sufficient for testing. SUGGEST REPEAT ING AS CLINICALLY INDICATED CHLORIDE - URINE 24 HOUR 0D mmol/ CHOLESTEROL 0D mg/dl CK TOTAL 0D u/l CKMB 0D < 6.7 < 4.8 ng/ml 4 Reviewed: 1/04/13

5 S CKMB RELATIVE INDEX 0D CMV IgG 0D NEGATIVE NEGATIVE CMV IgM 0D NEGATIVE NEGATIVE CO2 0D <10 >45 mmol/l CORTISOL 0D ug/dl AM COLLECTION ug/dl PM COLLECTION ug/dl CPK TOTAL 0D u/l CREATININE 0D mg/dl CREATININE - FLUID 0D mg/dl CREATININE - URINE 24 HOUR 0D mg/24hr CRP 0D mg/l CRP - SENSITIVITY 0D <3.0 <3.0 mg/l D-DIMER 0D ng/ml DDU A result less than <230 ng /ml DDU correlates with the absence of thrombosis in a patient with low and moderate pre-test probability of thrombosis. DIGOXIN 0D >2.5 ng/ml DRUG SCREEN - SERUM Expected values: ng/ml 4-6 hours post administration ACETAMINOPHEN 0D > 150 ug/ml ACETAMINOPHEN VALUES ARE RELATED TO TIME OF INGESTION. TOXIC VALUES > 50 ug/ml 12 hour post ingestion > 100 ug/ml 8 hour post ingestion > 200 ug/ml 4 hour post ingestion 5 Reviewed: 1/04/13

6 S BARBITURATES 0D NEGATIVE NEGATIVE BENZODIAZEPINES 0D NEGATIVE NEGATIVE ETHANOL 0D <10 <10 mg/dl SALICYLATE 0D >40 mg/dl TOXIC VALUES ACUTE INGESTION > 80 mg/dl CHRONIC INGESTION > 40 mg/dl TRICYCLIC ANTIDEPRESSANTS 0D NEGATIVE NEGATIVE CUT OFF VALUE BARBITURATES < 0.5 ug/ml TRICYCLIC ANTIDEPRESSANTS < 300 ng/ml BENZODIAZEPINES < 200 ng/ml DRUG SCREEN - URINE SERUM DRUG SCREENS ARE PERFORMED USING THE CUT OFF LEVELS LISTED ABOVE. THESE RESULTS SHOULD BE USED FOR MEDICAL PURPOSES ONLY ARE NOT FOR EMPLOYEE SCREENING OR LEGAL PURPOSES. WE SUGGEST CLINICAL CORRELATION AND CONFIRMATORY DRUG ING IF INDICATED. AMPHETAMINE CLASS 0D NEGATIVE NEGATIVE BARBITURATES 0D NEGATIVE NEGATIVE BENZODIAZEPINES 0D NEGATIVE NEGATIVE CANNABINOIDS 0D NEGATIVE NEGATIVE COCAINE / METABOLITE 0D NEGATIVE NEGATIVE METHADONE 0D NEGATIVE NEGATIVE OPIATES 0D NEGATIVE NEGATIVE OXYCODONE 0D NEGATIVE NEGATIVE PHENCYCLIDINE 0D NEGATIVE NEGATIVE 6 Reviewed: 1/04/13

7 S CUT OFF VALUE AMPHETAMINE CLASS < 1000 ng/ml BARBITURATES < 200 ng/ml BENZODIAZEPINES < 300 ng/ml CANNABINOIDS < 50 ng/ml COCAINE/METABOLITE < 300 ng/ml METHADONE < 300 ng/ml OPIATES < 300 ng/ml PHENCYCLIDINE < 25 ng/ml OXYCODONE < 100 ng/ml URINE DRUG SCREENS ARE PERFORMED USING THE CUT OFF LEVELS LISTED ABOVE. CROSS REACTIVITY WITH OTHER MEDICATIONS MAY OCCUR. WE SUGGEST CLINICAL CORRELATION AND CONFIRMATORY DRUG ING IF INDICATED. THESE RESULTS ARE FOR MEDICAL PURPOSES ONLY AND SHOULD NOT BE USED FOR EMPLOYEE SCREENING OR LEGAL PURPOSES. A COMPREHENSIVE OF CROSS-REACTING DRUGS IS AVAILABLE IN THE LABORATORY. DRVVT 0D SEC ETHANOL - SERUM 0D < 10 < 10 mg/dl ETHANOL - URINE 0D < 10 < 10 mg/dl FACTOR 2 0D % FACTOR 5 0D % FACTOR 5 LEIDEN 0D NO MUTATION NO MUTATION FACTOR 7 0D % FACTOR 8 0D % FACTOR 9 0D % FACTOR 10 0D % FACTOR 11 0D % FACTOR 12 0D % FERRITIN 0D ng/ml 7 Reviewed: 1/04/13

8 S FETAL FIBRONECTIN 0D NEGATIVE NEGATIVE FETAL HGB ALKALINE DENATURE 0D % 1M M M M FIBRINOGEN 0D < 100 mg/dl FLUID IMMUNOQUANTITATION FLUID IMMUNO IgA 0D 0 0 mg/dl FLUID IMMUNO IgG 0D 0 0 mg/dl FLUID IMMUNO IgM 0D 0 0 mg/dl FLUID KAPPA 0D 0 0 mg/dl FLUID LAMBDA 0D 0 0 mg/dl FOLATE 0D ng/ml GC DNA PROBE 0D NEGATIVE NEGATIVE GENTAMICIN - PEAK 0D > 10.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GENTAMICIN - RANDOM 0D >2.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GENTAMICIN - THROUGH 0D > 2.0 ug/ml 8 Reviewed: 1/04/13

9 S PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml GGT 0D u/l GLUCOSE 0D < 45 > 450 mg/dl GLUCOSE - CHALLENGE 0D mg/dl POST DOSE GLUCOSE - CSF 0D mg/dl GLUCOSE - FLUID 0D mg/dl GLUCOSE - 2 HOUR PP 0D mg/dl GLUCOSE TOLERANCE FASTING 0D < 45 > 450 mg/dl < 45 > 450 1/2 HOUR 0D < 40 > 350 mg/dl 1 HOUR 0D < 40 > 350 mg/dl 1 1/2 HOUR 0D < 40 > 350 mg/dl 2 HOUR 0D < 40 > 350 mg/dl 3 HOUR 0D < 40 > 350 mg/dl < 40 > HOUR 0D < 40 > 350 mg/dl < 40 > HOUR 0D < 40 > 350 mg/dl < 40 > 350 GLUCOSE - URINE 24 HOUR 0D mg/24hr 9 Reviewed: 1/04/13

10 S HAPTOGLOBIN 0D mg/dl HCG 0D < 5.0 < 5.0 miu/ml GROUP HCG-QUANT miu/ml Male: Less than 5 Non-pregnant females: Less than 5 Indeterminant females: 5-25 Weeks of pregnancy: miu/ml , , , , , , , , , , , , ,000-63, ,000-71, ,000-58,000 HcTi DABIGATRAN 0D 0 0 ug/ml Peak (2 hours post dose): ug/ml Through (12 hours post dose): ug/ml *****************ATTENTION********************* This test was developed and it's performance characteristics determined by Medical Laboratory at Long Island Jewish Medical Center. It has not been cleared or approved by the US Drug and Food Administration. The results of this test should be used in conjunction with clinical findings and coagulation tests including APTT. HDL CHOLESTEROL 0D mg/dl 10 Reviewed: 1/04/13

11 S HEMOGLOBIN A1C 0D % High risk (pre-diabetic) % Diabetic - diagnostic > 6.5 % ADA diabetic treatment goal < 7.0 % HbA1C values may not accurately reflect mean blood glucose in patients with Hb variants. Suggest clinical correlation. HEMOGLOBIN A 0D % 1D M M HEMOGLOBIN C 0D 0 0 % HEMOGLOBIN F 0D % 1M M HEMOGLOBIN S 0D 0 0 % HEPARIN INDUCED THROMBOCYTOPENIA 0D HEPARIN SCREEN HEPARIN SCREEN APTT 0D SEC HEPARIN SCREEN PT 0D SEC HEPATITIS A ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B CORE IgM ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIGEN 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIBODY 0D NEGATIVE NEGATIVE HEPATITIS B SURFACE ANTIBODY - Quant. 0D miu/ml NEGATIVE = < 5.0 miu/ml INDETERMINATE = miu/ml POSITIVE = > 12.0 miu/ml 11 Reviewed: 1/04/13

12 S HEPATITIS C ANTIBODY 0D NEGATIVE NEGATIVE MOLECULAR WT. KININOGEN 0D % PHOSPOLIPID DRVVT 0D RATIO HIV - 1/2 ANTIBODY SCREEN by EIA 0D NON-REACTIVE NON-REACTIVE IMMUNOGLOBULIN - SERUM IGA QUANTITATIVE 0D mg/dl IGE QUANTITATIVE 0D IU/mL 1M IGG QUANTITATIVE 0D mg/dl IGM QUANTITATIVE 0D mg/dl Reviewed: 1/04/13

13 S INFLUENZA A ANTIGEN 0D NEGATIVE NEGATIVE INFLUENZA B ANTIGEN 0D NEGATIVE NEGATIVE INHIBITOR ASSAY 0D 0 0 BU INR 0D > 4.0 IRON 0D ug/dl IRON BINDING CAPACITY - 0D ug/dl UNSATURATED (UIBC) LACTATE 0D > 4.0 mmol/l LACTATE - CSF 0D mmol/l 3D D LD 0D U/L LDL - DIRECT 0D mg/dl LEUK ALK PHOSPHATASE 0D LIPASE 0D U/L LITHIUM 0D >1.5 mmol/l LYME DISEASE SCREEN 0D NEGATIVE NEGATIVE MAGNESIUM 0D < 1.0 >7.0 mg/dl MAGNESIUM - URINE 24 HOUR 0D mg/24 Hr MALARIA SCREEN 0D NEGATIVE NEGATIVE MEASLES IgG 0D NEGATIVE NEGATIVE METHOTREXATE 0D umol/l <= 5.0 umol/l at 24 hours <= 1.0 umol/l at 48 hours <= 0.1 umol/l at 72 hours 13 Reviewed: 1/04/13

14 S MIXING STUDY PT INHIBITOR SCREEN - 0 HR 0D SEC PT INHIBITOR SCREEN - 2 HR 0D SEC PT NORMAL POOL PLASMA 0D SEC PTT INHIBITOR SCREEN - 0 HR 0D SEC PTT INHIBITOR SCREEN - 2 HR 0D SEC PTT NORMAL POOL PLASMA 0D SEC MONONUCLEOSIS 0D NEGATIVE NEGATIVE MUMPS VIRUS IgG 0D NEGATIVE NEGATIVE OCCULT BLOOD 0D NEGATIVE NEGATIVE OSMOLALITY 0D mosmo/kg OSMOLALITY - 24 HOUR URINE 0D mosmo/kg OSMOLALITY - RANDOM URINE 0D mosmo/kg P2Y12 PLATELET REACTIVITY 0D PRU Assay performance may be affected by Hematocrit values < 33% or > 53% or a Platelet count < 119 or > 502 k/ul PHENOBARBITAL 0D > 50 ug/ml PHENYTOIN (DILANTIN) 0D > 30 ug/ml PHOSPHORUS - INORGANIC 0D < 1.0 mg/dl 6W < M < < < 1.0 PHOSPHORUS - INORGANIC - URINE 24 H 0D mg/dl PLASMA VISCOSITY 0D Reviewed: 1/04/13

15 S PLASMINOGEN ACTIVITY 0D % POTASSIUM 0D < 3.0 > 6.2 mmol/l POTASSIUM - CSF 0D meq/l CSF Potassium is generally 70% of plasma value POTASSIUM - FLUID 0D meq/l CSF RBC LYMPH PERITONEAL PLEURAL FLUID PROSTATIC FLUID SALIVA SYNOVIAL FLUID TRANSUDATES POTASSIUM - URINE 24 HOUR 0D mmol/24h PRE-ALBUMIN 0D mg/dl pro-bnp 0D < 300 < 300 pg/ml ACUTE CONGESTIVE HEART FAILURE is UNLIKELY if NT-proBNP is < 300 pg/ml. CONSIDER ACUTE CONGESTIVE HEART FAILURE if: NT-proBNP RESULT < 50 YEARS > 450 pg/ml YEARS > 900 pg/ml > 75 YEARS > 1800 pg/ml All results require clinical correlation. Consider obtaining a baseline or "dry" NT-proBNP level when the patient is stabilized, so that subsequent levels can be compared to that value. Patients with recurrent CHF may have elevated NT-proBNP levels. Acute failure episodes generally produce levels at least 25% greater than baseline levels. The above values are derived from a large multi-center international study, "Januzzi, JL, et al, European Heart Journal, 2006; 27: " PROTEIN - TOTAL 0D g/dl 15 Reviewed: 1/04/13

16 S PROTEIN - CSF 0D mg/dl 29D PROTEIN - URINE RANDOM 0D <12 <12 mg/dl PROTEIN - URINE 24 HOUR 0D <150 <150 mg/24 Hr PROTEIN C ACTIVITY 0D % PROTEIN C ANTIGEN 0D % PROTEIN S ACTIVITY 0D % PROTEIN S ANTIGEN, FREE 0D % PROTIME 0D SEC PTH INTACT 0D pg/ml RETIC PROFILE RETIC % 0D % 8D M ABSOLUTE RETIC # 0D x6/uL RETIC % - MANUAL 0D % RHEUMATOID FACTOR 0D <14.0 <14.0 IU/mL ROTAVIRUS 0D NEGATIVE NEGATIVE RPR 0D NonReactive NonReactive RSV ANTIGEN 0D NEGATIVE NEGATIVE RUBELLA IgG 0D < 10.0 < 10.0 IU/mL NEGATIVE < 9.9 POSITIVE POSITIVE > Reviewed: 1/04/13

17 S SALICYLATES 0D >40 mg/dl TOXIC VALUES ACUTE INGESTION > 80 mg/dl CHRONIC INGESTION > 40 mg/dl SEDIMENTATION RATE 0D mm/hr SICKLE CELL SCREEN 0D NEGATIVE NEGATIVE SODIUM 0D <125 >155 mmol/l 29D <120 >160 SODIUM - CSF 0D meq/l SODIUM -FLUID 0D meq/l SODIUM - URINE 24 HOUR 0D mmol/24h SPINAL IMMUNOQUANTITATION SPINAL IgA 0D mg/dl SPINAL IgG 0D mg/dl SPINAL IgM 0D mg/dl T3 TOTAL 0D ng/ml T UPTAKE 0D TBI T4 0D ug/dl THEOPHYLLINE 0D >20 ug/ml THROMBIN TIME 0D SEC TOBRAMYCIN - PEAK 0D > 10 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml 17 Reviewed: 1/04/13

18 S TOBRAMYCIN - RANDOM 0D ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml TOBRAMYCIN - THROUGH 0D > 2.0 ug/ml PEAK TROUGH ONCE DAILY THERAPY N/A < 1 ug/ml TRADITIONAL DOSING 4-10 ug/ml < 1 ug/ml SYNERGY DOSING 3-4 ug/ml < 2 ug/ml TOXIC VALUES > 10 ug/ml > 2 ug/ml TOXOPLASMA IgG 0D NEGATIVE NEGATIVE TOXOPLASMA IgM 0D NEGATIVE NEGATIVE TRICYCLIC ANTIDEPRESSANTS 0D NEGATIVE NEGATIVE TROPONIN-T 0D < = 0.06 < = 0.06 ng/ml TRIGLYCERIDES 0D mg/dl TSH 0D uiu/ml URIC ACID 0D mg/dl URIC ACID (24 HR. URINE) 0D mg/24 hrs. VANCOMYCIN - RANDOM 0D >25 ug/ml Reference Range Trough ug/ml Toxic > 25 ug/ml Random values require clinical correlation VANCOMYCIN - TROUGH 0D >25 ug/ml Vancomycin trough levels should be rapidly reached and maintained at ug/ml for life threatening MRSA infections such as sepsis, endocarditis, osteomyelitis and pneumonia. A first trough level should be drawn before the 3rd or 4th dose. Risk of renal toxicity is increased for levels >15 ug/ml, in patients on other nephrotoxic drugs, who are hemodynamically unstable, have unstable renal function, or are on vancomycin therapy for >14 days. Renal function with creatinine levels should be monitored for those patients. 18 Reviewed: 1/04/13

19 S VARICELLA ZOSTER ANTIBODY 0D NEGATIVE NEGATIVE VISCOSITY PLASMA 0D VISCOSITY SERUM 0D VISCOSITY WHOLE BLOOD 0D VITAMIN B12 0D pg/ml VWF ACTIVITY 0D % THIS IS AN ENHANCED LATEX IMMUNO-TURBIDIMETRIC ASSAY. THE ESTABLISHED BY NSLIJHS LABORATORY IS FOR PATIENTS OF ALL BLOOD TYPES. THERE IS VARIABILITY DUE TO BLOOD TYPE (ER VALUES FOR TYPE O). THE RESULT IS ALSO AFFECTED BY ACUTE PHASE REACTION AND SHOULD BE INTERPRETED IN THE CONTEXT OF THE CLINICAL SETTING FOR THE PATIENT. THE PRESENCE OF RHEUMATOID FACTOR >200 IU/ML MAY CAUSE FALSE ELEVATION OF VWF ACTIVITY. VWF ANTIGEN 0D % 19 Reviewed: 1/04/13